# Financial Results for FY2017 First Quarter 

August 1, 2017

SUMITOMO CHEMICAL

## (Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace;
Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

## Contents

## Financial Results for FY2017 First Quarter

Financial Summary ..... 4
Net Sales by Business Segments ..... 5
Operating Income by Business Segments ..... 6
Segment Analysis ..... 7
Consolidated Balance Sheets ..... 12
Consolidated Statements of Cash Flows ..... 13
Impact from Adoption of IFRS (FY2017) ..... 14
(Reference)
Net Sales
by Business Segments (Quarterly) ..... 16
Operating Income by Business Segments (Quarterly) ..... 17
Major Group Companies ..... 18

## Financial Results for FY2017 First Quarter

## Financial Summary

Unit; billions of yen

|  | $\begin{gathered} \text { FY2016 } \\ \text { 1st Quarter } \end{gathered}$ | $\begin{gathered} \text { FY2017 } \\ \text { 1st Quarter } \end{gathered}$ | Difference | Ratio |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 456.6 | 508.5 | 52.0 | 11.4\% |
| Operating income | 25.3 | 37.6 | 12.3 | 48.6\% |
| (Equity in earnings of affiliates) | (10.2) | (7.7) | (-2.5) | - |
| (Net exchange gain / loss) | (-9.3) | (0.5) | (9.8) | - |
| Ordinary income | 25.8 | 46.2 | 20.3 | 78.7\% |
| (Extraordinary gain / loss) | (-0.5) | (9.1) | (9.6) | - |
| (Income taxes) | (-4.8) | (-10.4) | (-5.6) | - |
| Net income | 20.6 | 44.9 | 24.4 | - |
| (Net income attributable to non-controlling interests) | (-8.4) | (-13.4) | (-5.0) | - |
| Net income attributable to owners of the parent | 12.2 | 31.6 | 19.3 | 158.3\% |
| ROE | 1.7\% | 3.8\% |  |  |
| Exchange rate (yen/USD) | 108.04 | 111.09 |  |  |
| Naphtha price (yen/KL) | 31,600 | 39,000 |  |  |
| Overseas sales ratio | 60.6\% | 62.1\% |  |  |

## Net Sales by Business Segments

Unit; billions of yen

|  | FY2016 <br> 1st Quarter | FY2017 1st Quarter | Difference | Ratio | $\begin{gathered} \text { Sales } \\ \text { Price } \\ \text { Variance } \end{gathered}$ | Shipping Volume Variance | Foreign Currency Conversion Variance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Petrochemicals \& Plastics | 137.0 | 156.5 | 19.6 | 14.3\% | 14.5 | 3.4 | 1.7 |
| Energy \& Functional Materials | 47.0 | 59.3 | 12.3 | 26.2\% | 2.0 | 10.1 | 0.2 |
| IT-related Chemicals | 86.0 | 90.8 | 4.8 | 5.5\% | -5.5 | 5.9 | 4.3 |
| Health \& Crop Sciences | 64.0 | 65.2 | 1.2 | 1.8\% | -3.5 | 3.5 | 1.2 |
| Pharmaceuticals | 111.7 | 124.8 | 13.1 | 11.7\% | 0.0 | 11.5 | 1.5 |
| Others \& Adjustments | 10.9 | 12.0 | 1.1 | 9.8\% | 0.0 | 1.1 | 0.0 |
| Total | 456.6 | 508.5 | 52.0 | 11.4\% | 7.5 | 35.5 | 9.0 |

## Analysis



## Operating Income by Business Segments

Unit; billions of yen

|  | FY2016 1st Quarter | FY2017 1st Quarter | Difference | Price Variance | Cost <br> Variance | Shipping Volume Variance and Other | Total |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Petrochemicals \& Plastics | 1.8 | 10.3 | 8.5 | 8.0 | 0.0 | 0.5 | 8.5 |
| Energy \& Functional Materials | 0.7 | 4.6 | 3.9 | 1.0 | 0.0 | 2.9 | 3.9 |
| IT-related Chemicals | 1.4 | 3.0 | 1.6 | -4.5 | 2.0 | 4.1 | 1.6 |
| Health \& Crop Sciences | 9.1 | 3.0 | -6.1 | -3.5 | -1.0 | -1.6 | -6.1 |
| Pharmaceuticals | 15.3 | 20.3 | 5.0 | 0.0 | -1.5 | 6.5 | 5.0 |
| Others \& Adjustments | -3.0 | -3.7 | -0.7 | 0.0 | 0.5 | -1.2 | -0.7 |
| Total | 25.3 | 37.6 | 12.3 | 1.0 | 0.0 | 11.3 | 12.3 |

## Analysis

+11.3

|  |  |  | +11.3 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | +1.0 | $\pm 0.0$ |  | 37.6 |
| 25.3 |  |  | Pharmaceuticals IT-related Chemicals |  |
| FY2016 1st Quarter | Price | Cost | Volume etc. | FY2017 <br> 1st Quarter |

## Petrochemicals \& Plastics - Segment Analysis -

## Sales



## Operating income



Total $¥ 156.5$ billion ( +19.6 from FY2016 1st Quarter)
Sales price +14.5

Volume +3.4

Foreign exchange +1.7

- Improve in market price of MMA and synthetic resins
- Consolidation of Sumika Polycarbonate as subsidiary
- Increase in shipment of Rabigh products

Total $¥ 10.3$ billion ( +8.5 from FY2016 1 st Quarter )
Price variance
+8.0
Cost variance

$$
0
$$

Volume variance etc. ■ Increase in shipment of Rabigh products

$$
+0.5
$$

- Better profit margin on synthetic resins and MMA

Increase in shipment of Rabigh products

## Energy \& Functional Materials - Segment Analysis -

## Sales



## Operating income



## Total $¥ 59.3$ billion (+12.3 from FY2016 1st Quarter )

Sales price
+2.0

- Higher market price for aluminum
- Increase in shipment of resorcinol
- Increase in shipment of engineering plastics


## Foreign exchange

$$
+0.2
$$

## Total $¥ 4.6$ billion (+3.9 from FY2016 1st Quarter )

Price variance
+1.0

Cost variance

$$
0
$$

Volume variance etc.

- Increase in shipment of resorcinol
+2.9 $\quad$ Increase in shipment of engineering plastics


## IT-related Chemicals - Segment Analysis -

## Sales



## Total $¥ 90.8$ billion ( +4.8 from FY2016 1st Quarter )

| Sales price | - Decline in selling price of polarizing film |
| :---: | :---: | :---: |
|  | -5.5 Decline in selling price of touchscreen panels |

Volume - Increase in shipment of touchscreen panels
+5.9 ■ Increase in shipment of polarizing film

## Foreign exchange

 $+4.3$Total $¥ 3.0$ billion ( +1.6 from FY2016 1st Quarter )
Price variance

- Decline in selling price of polarizing film
-4.5
- Decline in selling price of touchscreen panels

Cost variance

- Rationalization of the use of raw materials
$+2.0$

Volume variance etc. - Increase in shipment of touchscreen panels

$$
\text { +4.1 } \quad \text { Increase in shipment of polarizing film }
$$

## Health \& Crop Sciences - Segment Analysis -

## Sales <br> 

## Operating income



## Total ¥3.0 billion (-6.1 from FY2016 1st Quarter )

## Price variance

- Lower market price for feed additive

Cost variance
-3.5 methionine

- Increase in R\&D cost
-1.0
- Increase in cost of actuarial gain and loss

Volume variance etc. Negative impact of stronger yen
-1.6

- Lower market price for feed additive methionine
- New consolidation of Indian subsidiary +3.5


## Foreign exchange

 +1.2
## Pharmaceuticals - Segment Analysis -

## Sales



## Total $¥ 124.8$ billion ( +13.1 from FY2016 1 st Quarter )

Sales price 0

## Volume +11.5

Foreign exchange +1.5

- NHI price revision in Japan
- Increase in shipment of Latuda® in North America


## Operating income



Total $¥ 20.3$ billion ( +5.0 from FY2016 1st Quarter )
Price variance
0

Cost variance $-1.5$

Volume variance etc.
$+6.5$

- NHI price revision in Japan
- Increase in sales expense
- Increase in shipment of Latuda® in North America


## Consolidated Balance Sheets

|  | 31-Mar-17 | 30-Jun-17 | Difference |  | 31-Mar-17 | 30-Jun-17 | Difference |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Current assets | 1,231.1 | 1,282.5 | 51.3 | Liabilities | 1,699.5 | 1,734.4 | 34.9 |
| Cash and cash equivalents | 193.3 | 214.4 | 21.1 | Trade notes and accounts payable | 243.5 | 242.9 | -0.7 |
| Trade notes and accounts receivable | 455.2 | 446.9 | -8.4 | Interest-bearing Liabilities | 875.3 | 909.4 | 34.1 |
| Inventories | 409.4 | 428.8 | 19.4 | Others | 580.7 | 582.2 | 1.5 |
| Others | 173.2 | 192.4 | 19.2 | Net assets | 1,162.5 | 1,183.6 | 21.1 |
| Non-current assets | 1,630.9 | 1,635.6 | 4.7 | Shareholders' equity | 707.0 | 727.2 | 20.2 |
| Property, plant and equipment | 626.2 | 624.1 | -2.1 | Accumulated other comprehensive income | 113.3 | 107.4 | -6.0 |
| Intangible assets | 357.6 | 353.8 | -3.8 | Non-controlling interests | 342.2 | 349.1 | 6.9 |
| Investment and other assets | 647.1 | 657.7 | 10.6 |  |  |  |  |
| Total | 2,862.1 | 2,918.0 | 56.0 | Total | 2,862.1 | 2,918.0 | 56.0 |
|  |  |  |  | Shareholders' equity ratio | 28.7\% | 28.6\% | -0.1\% |
|  |  |  |  | D/E ratio | 0.8 | 0.8 | 0.0 |

SUMITOMO CHEMICAL

## Consolidated Statements of Cash Flows



Unit; billions of yen

| IFRS <br> (Japanese GAAP) | Japanese <br> GAAP | IFRS | Difference | Reasons |
| :--- | ---: | ---: | ---: | :--- |
| Sales revenue <br> (Net sales) | $2,190.0$ | $\mathbf{2 , 1 7 0 . 0}$ | $\Delta 20.0$ | - Derecognition of SWAP <br> transactions |
| Core operating income <br> (Operating income) | $\mathbf{1 6 5 . 0}$ | $\mathbf{2 0 0 . 0}$ | $\mathbf{3 5 . 0}$- Inclusion of income from <br> equity method <br> - No Amortization of goodwill |  |
| Net income attributable to <br> owners of the parent | $\mathbf{1 0 0 . 0}$ | $\mathbf{1 0 0 . 0}$ |  |  |

## Core operating income

Core operating income shows ordinary profitability of businesses, calculated by excluding gain/loss and income/expense incurred by extraordinary reasons from operating income defined in IFRS. It includes income/loss from equity method. It will be used for management report to measure business performance and will be disclosed as segment profit/loss.

## (Reference)

## Net Sales by Business Segments (Quarterly)

Unit; billions of yen

|  | FY2016 |  |  |  | FY2017 | FY2017 (estimated) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3 Q | 4Q | 1 Q | 1st Half | 2nd Half |
| Petrochemicals \& Plastics | 137.0 | 128.7 | 148.4 | 158.0 | 156.5 | 300.0 | 340.0 |
| Energy \& Functional Materials | 47.0 | 47.5 | 51.5 | 59.9 | 59.3 | 120.0 | 130.0 |
| IT-related Chemicals | 86.0 | 88.7 | 95.1 | 88.6 | 90.8 | 190.0 | 195.0 |
| Health \& Crop Sciences | 64.0 | 61.8 | 66.1 | 127.4 | 65.2 | 150.0 | 230.0 |
| Pharmaceuticals | 111.7 | 102.6 | 115.5 | 114.5 | 124.8 | 235.0 | 245.0 |
| Others \& Adjustments | 10.9 | 14.7 | 12.7 | 16.1 | 12.0 | 25.0 | 30.0 |
| Total | 456.6 | 444.0 | 489.3 | 564.5 | 508.5 | 1,020.0 | 1,170.0 |

## Operating Income by Business Segments (Quarterly)

Unit; billions of yen

|  | FY2016 |  |  |  | FY2017 | FY2017 (estimated) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 30 | 4Q | 1 Q | 1st Half | 2nd Half |
| Petrochemicals \& Plastics | 1.8 | 4.9 | 10.9 | 9.1 | 10.3 | 13.0 | 14.0 |
| Energy \& Functional Materials | 0.7 | 1.5 | 3.0 | 2.1 | 4.6 | 5.0 | 7.0 |
| IT-related Chemicals | 1.4 | 1.1 | 6.5 | 1.4 | 3.0 | 11.0 | 10.0 |
| Health \& Crop Sciences | 9.1 | 3.8 | 3.7 | 29.6 | 3.0 | 13.0 | 47.0 |
| Pharmaceuticals | 15.3 | 12.6 | 18.2 | 9.0 | 20.3 | 28.0 | 29.0 |
| Others \& Adjustments | -3.0 | -1.8 | -3.2 | -3.1 | -3.7 | -5.0 | -7.0 |
| Total | 25.3 | 21.9 | 39.0 | 48.1 | 37.6 | 65.0 | 100.0 |

## Major Group Companies

| Company | Net Sales |  | Profit Trends |
| :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { FY2016 } \\ \text { 1st Quarter } \end{gathered}$ | FY2017 1st Quarter |  |
| The Polyolefin Company (Singapore) (millions of USD) | 267 | 278 | $\nearrow$ Maintaining due to better margins |
| Petrochemical Corporation of Singapore <br> (millions of USD) | 572 | 599 | $\longrightarrow$ Maintaining due to better margins |
| Rabigh Refining and Petrochemical Company (millions of SAR) | 4,947 | 6,702 | Lower margin on oil refining and other factors |
| Dongwoo Fine-Chem <br> (billions of KRW) | 517 | 527 | Decreased due to lower selling price and other factors despite higher sales volume |
| Valent U.S.A. and Subsidiaries <br> (millions of USD) | 191 | 166 | Decreased due to timing difference and other factors |

